Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
NCT00725985 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- April 30, 2012
- Enrollment
- 617 (actual)
- Sites
- 158
Conditions
As the registry lists them; a condition with its own page is linked.